Oral montelukast compared with inhaled salmeterol to prevent exercise- induced bronchoconstriction: A randomized, double-blind trial

Annals of Internal Medicine

Volumn 132, Issue 2, 2000, Pages 97-104

  Edelman, Jonathan M ^a   Turpin, Jennifer A ^a   Bronsky, Edwin A ^b   Grossman, Jay ^c   Kemp, James P ^d   Ghannam, Asma F ^a   DeLucca, Paul T ^a   Gormley, Glenn J ^a   Pearlman, David S ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Intermountain Clinical Research   (United States)

^c VIVRA Research   (United States)

^d ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^e Respiratory Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONTELUKAST; SALMETEROL;

ADOLESCENT; ADULT; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE INDUCED ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033982571     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-2-200001180-00002     Document Type: Article

References (30)

1. Cypcar D, Lemanske RF Jr. Asthma and exercise. Clin Chest Med. 1994; 15:351-68.
2. Israel E. Moderating the inflammation of asthma: inhibiting the production or action of products of the 5-lipoxygenase pathway. Ann Allergy. 1994;72: 279-84.
3. Dahlen S, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980;288:484-6.
4. 4, and histamine in normal human subjects. Thorax. 1984; 39:500-4.
5. 4 in humans. Am Rev Respir Dis. 1985;131:368-72.
6. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 1997;52:1030-5.
7. 4 after exercise challenge in children with asthma. J Allergy Clin Immunol. 1992;89:1111-9.
8. Kemp JP, Dockhorn RJ, Busse WW, Bleecker ER. Van As A. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med. 1994;150:1612-5.
9. Newnham DM, Ingram CG, Earnshaw J, Palmer D, Dhillon DP. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med. 1993;87: 439-44.
10. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994;88:363-8.
11. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998;339:141-6.
12. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99:655-9.
13. 4 receptor antagonist. N Engl J Med. 1990;323:1736-9.
14. 4 receptor antagonist. Am Rev Respir Dis. 1992:145:746-9.
15. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther. 1997;62:556-61
16. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, et al, Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to-14-year-old children with asthma. J Pediatr. 1998;133:424-8.
17. Left JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mid asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339: 147-52.
18. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med, 1995;152:1107-36.
19. Eggleston PA, Guerrant JL. A standardized method of evaluating exercise-induced asthma. J Allergy Clin Immunol. 1976;58:414-25.
20. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997.
21. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 1996;153:65-9.
22. Freezer NJ, Croasdell H, Doull IJ, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Eur Respir J. 1995;8:1488-93.
23. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol Chest. 1995;108:1235-9.
24. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Drug Saf. 1997;16:295-308.
25. Reiss T, Sorkness CA, Stricker W, Botto A, Busse W, Kundu S, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax. 1997;52:45-8.
26. Smyth ET, Pavord ID, Wong CS, Wisniewski AF, Williams J, Tattersfield AE. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ. 1993;306:543-5.
27. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients Lancet. 1995;46:201-6.
28. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention: A Pocket Guide for Physicians and Nurses. Bethesda, MD: National Institutes of Health;1998.
29. Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy. J Allergy Clin Immunol. 1996:98:475-80.
30. Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child. 1992;67:1014-7